VTYX - Strong Gap-Up on Catalyst, Watching for Delayed SetupThe stock is showing a strong gap-up move on what appears to be a solid catalyst. However, given the current trading environment, which remains unfavorable for sustained breakouts, I’ll be watching for a potential delayed-reaction setup to develop over the coming days or weeks.
6.20 - 5.40 is a local support for potential pullback.
Chart:
Autoimmunetherapies
Roivant Sciences (ROIV): A Multibagger Stock Opportunity
Roivant Sciences (ROIV) is poised for significant growth with a strong pipeline, including potential blockbusters like Batoclimab and Brepocitinib in the autoimmune space. Recent deals, including the $5.2B sale of Telavant, have strengthened their balance sheet and set the stage for future profitability. Upcoming Q4 catalysts, a $1.5B buyback program, and a solid focus on pulmonary hypertension therapies make ROIV an undervalued gem at its current price.
Personal Note: Hi, I'm sharing insights on stocks with strong catalysts like ROIV. Follow me for more deep dives and stock picks.

